Standout Papers
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009)
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (2015)
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial (2016)
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (2012)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial (2012)
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (2019)
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer (2016)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
- An immune-active tumor microenvironment favors clinical response to ipilimumab (2011)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (2017)
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study (2013)
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma (2016)
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type (2014)
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016)
Immediate Impact
61 by Nobel laureates 31 from Science/Nature 256 standout
Citing Papers
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Cutaneous melanoma
2023 Standout
Works of Omid Hamid being referenced
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
2019 Standout
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Omid Hamid | 20826 | 7834 | 9634 | 407 | 25.6k | |
| Ignacio Melero | 15374 | 6438 | 16403 | 384 | 27.3k | |
| Achim A. Jungbluth | 9943 | 7650 | 9849 | 283 | 20.5k | |
| Paolo A. Ascierto | 17638 | 11139 | 6919 | 744 | 24.4k | |
| David P. Carbone | 13377 | 10758 | 8966 | 408 | 26.4k | |
| Mario Sznol | 13619 | 5480 | 7664 | 266 | 19.4k | |
| Padmanee Sharma | 19463 | 6273 | 13562 | 254 | 27.6k | |
| Alfred E. Chang | 11203 | 4135 | 9573 | 294 | 20.5k | |
| Georgina V. Long | 24765 | 16231 | 8971 | 669 | 33.3k | |
| Robert H. Vonderheide | 14819 | 6700 | 13907 | 221 | 24.3k | |
| Catherine Sautès‐Fridman | 14429 | 8164 | 15615 | 300 | 28.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...